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Abstract
Background: Lower respiratory tract infections continue to contribute significantly to morbidity and mortality
across all age groups globally. In sub-Saharan Africa, many studies of community acquired pneumonia in adults
have focused on HIV-infected patients and little attention has been given to risk factors and etiologic agents in an
urban area with a more moderate HIV prevalence.
Methods: We prospectively enrolled 77 patients admitted to a 280 bed teaching hospital in Kenya with
radiographically confirmed community acquired pneumonia from May 2019 to March 2020. The patients were
followed for etiology and clinical outcomes. Viral PCR testing was performed using the FTD respiratory pathogen-21
multiplex kit on nasopharyngeal or lower respiratory samples. Additional microbiologic workup was performed as
determined by the treating physicians.
Results: A potential etiologic agent(s) was identified in 57% including 43% viral, 5% combined viral and bacterial,
5% bacterial and 4% Pneumocystis. The most common etiologic agent was Influenza A which was associated with
severe clinical disease. The most common underlying conditions were cardiovascular disease, diabetes and lung
disease, while HIV infection was identified in only 13% of patients. Critical care admission was required for 24, and
31% had acute kidney injury, sometimes in combination with acute respiratory distress or sepsis.
Conclusion: Viruses, especially influenza, were commonly found in patients with CAP. In contrast to other studies
from sub-Saharan Africa, the underlying conditions were similar to those reported in high resource areas and point
to the growing concern of the double burden of infectious and noncommunicable diseases.
Keywords: Pneumonia, Viral pneumonia, Community acquired pneumonia, Sub-Saharan Africa, Kenya, Influenza,
Tuberculosis, Pneumocystis jirovecii, Diabetes, HIV
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Background
According to the Global Burden of Diseases (GBD),
lower respiratory tract infections (LRIs) were reported
to have caused 2.7 to 2.8 million deaths per year
from 2005 to 2015 and close to half of these were
among adults [1]. Sub-Saharan Africa (SSA) is disproportionately affected by a higher burden of lower respiratory tract infections which affect a much younger
population when compared to the North American
and European cohorts [2].
Studies on viral etiology of community acquired pneumonia (CAP) among adults within the sub-Saharan African region are scarce and where available, are often
combined with pediatric cohorts [3]. In addition, some
of the reports are from settings with very high HIV and
tuberculosis prevalence. The high prevalence of HIVassociated comorbidities, lack of control cohorts and absence of standard definitions make it difficult to consistently determine and define the overall burden of viral
lower respiratory disease or characterize disease by etiology [3]. In contrast, Kenya had an estimated HIV
prevalence of 4.9% in 2017 (6.1% in Nairobi), which
places it above most countries in other continents but
substantially lower than many countries of sub-Saharan
Africa [4]. The prevalence of non-communicable diseases (NCDs) such as obesity and diabetes mellitus has
been increasing in sub-Saharan Africa, creating new potential risk factors for CAP. These conditions have been
associated with increased susceptibility to viral infections
especially with influenza among diabetic patients [5–7].
Having recognized this inimical synergy, some countries,
such as South Africa, have designed and rolled out specific health care guidelines for the management of CAP
among susceptible groups including those with diabetes
mellitus [8].
Before the onset of the COVID-19 pandemic, influenza
was the most common cause of severe life threatening
and vaccine preventable viral lower respiratory disease
among adults worldwide [9–12]. In addition, numerous
other viral pathogens are recognized as important causes
of lower respiratory tract infections (LRTI). Respiratory
syncytial virus (RSV) is second to Influenza as a cause of
LRTI and shows winter seasonality similar to influenza
in temperate climates [13–16]. Human metapneumovirus and human parainfluenza virus are within the same
family of viruses as RSV and cause influenza-like symptoms in high-risk populations such as the elderly and
the immunocompromised [17–20]. In addition, adenoviruses [21] and rhinoviruses [11] are sometimes implicated as causes of LRTI.
We have therefore investigated the roles of these viral
pathogens as causes of CAP in a setting with moderate
levels of HIV and a growing prevalence of diabetes,
hypertension and other NCDs.
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Methods
Setting

The Aga Khan University hospital is a teaching hospital
in Nairobi with 280 beds that include 33 adult critical
care beds and over 20 medical specialties. The hospital
has been accredited by the Joint Commission International since 2013 and the laboratory has been accredited by SANAS since 2011 [22] and by the College of
American Pathologists since 2018.
Study design and definitions

We conducted a prospective observational study of inpatients with community acquired pneumonia from May
1st, 2019 until March 13th, 2020. The enrollment was
planned for a complete year but was terminated in
March due to the COVID-19 pandemic. The first case in
Kenya was reported on March 13, 2020. This series
therefore represents the spectrum of pre-COVID-19
pneumonia.
Patients over 18 years of age admitted with suspected
community acquired pneumonia were approached for
enrollment if they had a new infiltrate on pulmonary imaging with compatible symptoms such as cough, fever,
breathlessness, and production of sputum. Patients were
excluded if they had a pulmonary infection within 6
weeks of presentation or chronic lung disorders judged
to be significant enough to compromise interpretation of
the diagnosis or outcome of pneumonia. Chest images
(chest radiograph or CT Scan) obtained within 72 h of
admission were used to identify changes consistent with
lower respiratory infection findings, including opacities,
effusions, consolidations, and other findings. For patients
where both radiograph and CT were done, analysis was
based on CT findings. All enrolled patients were
followed up for critical care admission within 30 days
and for discharge status (alive/dead) or death within 30
days.
Acute kidney injury (AKI) was defined using the
KDIGO criteria [23]. Sepsis was defined using the Sepsis
3 criteria [24] as life-threatening organ dysfunction
caused by a dysregulated host response to infection
using the Sequential Organ Failure Assessment (SOFA)
to identify organ dysfunction (Ranieri et al., 2012). PSI
[25] and CURB65 [26] are validated scores for mortality
prediction (Shah BA et al., 2010) [27, 28] due to CAP
and were used as described. The PSI score is calculated
from the following parameters; age, sex, nursing home
resident, neoplastic disease, liver disease history, CHF
history, cerebrovascular disease history, renal disease
history, altered mental status, respiratory rate ≥ 30
breaths/min,
systolic
blood
pressure < 90mmhg,
temperature < 35 C or > 39.9 C, pulse ≥125 beats/min,
pH < 7.35, Blood urea ≥30 mg/dL or ≥ 11 mmol/L, Sodium < 130 mmol/L, glucose ≥14 mmol/L, hematocrit <
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30%, partial pressure of oxygen < 60 mm Hg and pleural
effusion on Xray. PSI scores of 1 to 3 are classified as
low risk, while PSI 4 to 5 are either moderate or high
risk. CURB65 is derived from the following: Confusion,
blood urea > 7 mmol/l, respiratory rate ≥ 30, systolic
blood pressure < 90 mm Hg diastolic blood pressure
≤ 60 mm Hg and Age ≥ 65 years. CURB65 scores of 0 to
2 are considered low risk; 3 is deemed to be moderate
risk, and 4 to 5 are regarded as high risk.
The WHO definition for severe acute respiratory infection (SARI) was used which includes a history of fever
or measured fever of ≥38 C° with onset in the last 10
days, cough and a requirement for hospitalization [29].
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(IQR 38–71.5) years and 57% were male. Eighty-three
percent had at least one pre-existing condition, including
cardiovascular disease (43%), followed by lung disease
(22%), diabetes mellitus type II (22%), and HIV (13%)
(Table 1). Almost half the study population (46%) had
used an antibiotic before admission, with the most frequently used being aminopenicillins (amoxicillin-clavulanate), macrolides (azithromycin) and cephalosporins
(cefuroxime or ceftriaxone).
Most of the enrolled patients had complaints of cough,
fever, difficult breathing, chest pain, and malaise, all of
which were present in at least half the patients. Seventynine percent fit criteria for severe acute respiratory illness (SARI).

Microbiological workup

After informed consent was obtained, nasopharyngeal
swabs were collected by a trained clinician using Sterile
Snappable Polystyrene & Viscose Amies Swabs (Deltalab,
Barcelona, Spain). Bronchoalveolar lavage (BAL) specimens
were used when available. Samples were stored at − 80 °C
until testing. Nucleic acid extraction was done using
QIAamp Viral RNA Minikit (Qiagen, Germany) as per
manufacturer’s instructions and reverse transcriptase-PCR
was done in a Rotor-gene Q thermal cycler (Qiagen,
Germany) using the FTD Respiratory pathogens 21 test
(Resp21; Fast Track Diagnostics, Luxembourg). Resp21 detects the following pathogens: influenza A virus (unknown
subtype); influenza A(H1N1) virus (swine-lineage); influenza B virus; human rhinovirus; human coronaviruses
NL63, 229E, OC43 and HKU1; human parainfluenza viruses 1, 2, 3 and 4; human metapneumoviruses A/B; human
bocavirus; human respiratory syncytial viruses A/B; human
adenovirus; enterovirus; human parechovirus and Mycoplasma pneumoniae. The first 73 patients were tested using
the Resp21 test. The same reagents were not available for
the last four patients, so their samples were tested for Influenza A, H1N1, Influenza B, RSV A and RSV B using Realstar Influenza Screen & Type RT-PCR Kit 4.0 and Realstar
RSV RT-PCR Kit 3.0 respectively (both produced by Altona
Diagnostics, Hamburg, Germany).
Other microbiological evaluations were performed as
requested by the treating physician and were not influenced by the study personnel. Microbiological reports
that were considered include sputum Gram stains and
cultures and blood cultures as well as influenza or RSV
rapid antigens. Pneumocystis PCR is highly sensitive but
not highly specific, so patients with positive Pneumocystis PCR were evaluated according to clinical characteristics and cytologic findings.

Results
Demographic profile

A total of 77 patients fitting the inclusion criteria were
enrolled in the study (Fig. 1). The median age was 54.5

Etiologies

Seventy-five of the 77 enrolled patients had a nasopharyngeal swab obtained for viral PCR using the Resp21
assay as part of the study protocol for 71 patients, while
four were tested by PCR using the Altona influenza and
RSV tests. Other tests were done as determined by the
admitting physician and included blood cultures (60)
and sputum [30]. Bronchoscopy was done in seven. A
potential etiology was identified in 44 (57%) of the patients (Table 2).
Viral agents were identified in 37 patients (48%) and
for 33 of these patients, the only pathogen identified was
a virus, while the other four had Mycobacteria tuberculosis or a pyogenic bacterium identified. Most of the viral
pathogens were identified from nasopharyngeal swabs,
but three of four oropharyngeal swabs and two of the
three BAL samples subjected to PCR had viruses identified. For the other four patients with BAL performed,
PCR was not performed on the BAL fluid, but was done
on nasopharyngeal swabs obtained upon enrollment and
one had a virus identified.
The most commonly identified virus that is consistently recognized as a lower respiratory pathogen was Influenza A, which was found in 18 patients. It was the
sole pathogen in 11 patients. It was found with one or
more other viruses in three patients, and with bacterial
infection in one patient who had pneumococcal
bacteremia. Diabetes mellitus was the most common comorbid condition among patients with Influenza A (9 of
18; 50%) and was found more commonly in those with
influenza than in those without (14 of 57; OR 3.07, 95%
CI 1.02–9.25, p = 0.046). Seven of the patients with influenza identified by PCR also had Influenza rapid antigen
testing done with only two of these positive, indicating
poor performance of the rapid antigen test.
Rhinoviruses were found in 18 patients, but in all but
four, were found with other viruses. For the four patients
with rhinovirus as the only potential pathogen, we included it as a cause of pneumonia while recognizing its
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Fig. 1 Flow chart of patient recruitment

role in LRI as being controversial. Other viruses that were
found included adenovirus, enteroviruses, parainfluenza,
RSV, parechovirus and human metapneumovirus. These
viruses were frequently found in combination. It is notable
that the two patients with adenovirus as the sole agent
presented with temperatures above 40 °C. Viruses were
isolated from patients throughout the 10 months of the recruitment period for total viruses (Fig. 2a) and for influenza, specifically (Fig. 2b).
Pyogenic bacteria were identified as pulmonary pathogens in seven patients; four with positive blood cultures
and three with potential pathogens from sputum specimens (Table 2). In addition, two of the patients had

positive AFB smears followed by positive cultures for M.
tuberculosis complex.
Of the 10 patients with HIV, three patients had
Pneumocystis pneumonia (PCP). These patients had
CD4 counts of 4, 22 and 340 cells/mm3. One of the patients with PCP had coinfection with both rhinovirus
and parainfluenza virus 4. The seven HIV positive patients without PCP included two with influenza, one
with rhinovirus-Klebsiella co-infection and another with
bacteremic pneumococcal pneumonia. No pathogen was
identified among three patients within this cohort and
neither of the two patients with TB presenting as CAP
was HIV-infected.
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Table 1 Patient characteristics

Table 2 Etiologic agents of pneumonia

Patient Category No. (%) of patients N = 77/ (%)

Type of infection and agents identified

n = 77 (%)

Age (Mean, SD)

None

33 (42.9)

54.0 (±16) Signs

60 years old or more 33 (42.9)

RR ≥ 30/min

6 (7.8)

Viral pathogen alone (single agent)

22 (28.6)

Gender

Heart rate ≥ 125/min

13 (16.9)

Male

44 (57.1)

Viral pathogen alone (multiple agents)

11 (14.3)

Temperature ≥ 39.5 or ≤ 35 13 (16.9)

Bacterial pathogen alone

4 (5.2)

SpO2 ≤ 92

38 (50.6)

Viral-bacterial co-infection

4 (5.2)

CVD

32 (41.6)

SBP < 90 mmHg

8 (10.4)

P. jirovecii

3 (3.9)

Diabetes

23 (29.9)

Laboratory findings

Lung disorders

26 (33.8)

WBC ≥ 10,000

34 (44.2)

Influenza A

18 (23.4)

CKD

9 (11.7)

Hemoglobin ≤10 g/dl

6 (7.8)

Rhinovirus

18 (23.4)

HIV infection

10 (13.0)

Platelets< 150,000

17 (22.1)

Adenovirus

6 (7.8)

Prior Antibiotics

35 (45.5)

BUN (Urea) > 7 mmol/l

16 (20.8)

Enterovirus

4 (5.3)

Serum sodium ≤130

10 (13.0)

Parainfluenza

3 (3.9)

Comorbidities

Lifestyle
Active Smoker

5 (6.5)

Imaging findings

Alcohol

17 (22.1)

Ground glass opacities

Symptoms

Viral agents:

27 (35.1)

Other Opacities

14 (18.2)

Multiple findingsa

10 (13.0)

Respiratory Syncytial Virus

2 (2.6)

Parechovirus

2 (2.6)

Human Metapneumovirus

1 (1.3)

Bacterial agents:
Blood culture (n = 60)

SARI

61 (79.2)

Consolidations

23 (29.9)

Fever

75 (97.4)

Effusions

2 (2.6)

E. coli

1 (1.3)

SOB (dyspnea)

60 (77.9)

Cavity

1 (1.3)

S. Typhi

1 (1.3)

Chest pain

62 (80.5)

Bilateral findingsb

27 (35.1)

S. pneumoniae

2 (2.6)

Malaise & fatigue

39 (50.6)

Case admissions

Sputum

18 (23.4)

Non-Critical

Bronchial wash culture (n = 7)
53 (68.9)

Weight loss

21 (27.3)

Critical Care

20 (26.0)

Wheezing

18 (23.4)

Critical Care and Intubated

4 (5.2)

CKD chronic kidney disease
CVD cardiovascular disease (hypertension, arrhythmias and heart failure)
SOB Shortness of breath
SARI Severe Acute Respiratory Illness; defined as a history of fever or
documented temperature of 38 °C and above and cough requiring
hospitalization within the last 10 days
a
Multiple findings included reticulonodular changes and peribronchial cuffing
that could not be placed into any of the above categories
b
Majority of the bilateral findings were opacities (13/27, 48%)

Outcomes

In this study, a low risk PSI score of 1–3 was recorded
in 73% of the patients. In the current study, 40% of the
patients had a CURB65 score of 0 and none had the high
risk scores of 4 to 5 despite the number of patients over
65 years (which adds one point to the score). Despite the
low PSI and CURB65 scores, a significant number of patients (34; 43.6%) patients had at least one complication
(Table 3). The most common was acute kidney injury
(31%), which was found alone in 22% and in combination with ARDS and/or sepsis in another 9%. In
addition, 30% percent of the admissions were to critical
care units. The average length of hospitalization was 7.4
days, though those in intensive care units spent a mean
of 8 days. Two (3%) of the study patients died within 30

M. tuberculosis

1 (1.3)

K. pneumoniae

1 (1.3)

Sputum (n = 39)
M. tuberculosis

1 (1.3)

S. pneumoniae

1 (1.3)

days, seven (9%) had readmission within the same
period.
The morbidity associated with influenza was greater
than that for other viruses or nonviral pneumonia as determined by the number of patients requiring critical
care treatment. Patients with influenza were more likely
to require critical care than those with other viral pneumonias (61%; OR 5.32, 95% CI 1.72–16.49, p = 0.004). In
contrast, 21% of those with other viruses not including
influenza and 22% of those with no virus identified required critical care.
Characteristics of the patients that died within 30 days

Two patients died within 30 days of enrollment, both of
whom had viral pneumonias. One was a 46 year-old female with diabetes mellitus and hypertension with Influenza A and adenovirus complicated by severe ARDS
who died from respiratory failure. The other patient was
a 59 year-old female with diabetes mellitus and multiple
myeloma. She had parainfluenza pneumonia and was
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Fig. 2 Viruses identified; the number on the left indicates the number of cases. A Virus isolation by month; May 2019 to March 2020. B Influenza
by month

managed on the non-critical ward and discharged after 7
days of hospitalization. She died 1 day after discharge.
Table 3 Pneumonia severity indices and level of care,
complications and outcome
Level of care

Total

Ward

53

PSI

CURB65

1

2

3

4

5

0

1

2

3

4/5

11

24

6

11

1

25

19

7

2

0

Critical care

20

1

7

4

3

4

6

6

5

2

0

Critical + vent

4

0

1

2

1

0

0

2

1

1

0

AKI

22

2

7

3

6

4

4

6

8

4

0

AKI with RF

2

0

0

1

0

1

0

1

1

0

0

RF

4

0

3

0

1

0

2

1

1

0

0

Complications

Outcome at 30 days
Mortality

2

0

1

1

0

0

1

1

0

0

0

Readmission

7

0

1

1

3

2

1

1

4

1

0

Discussion
This study is one of the few prospective studies of CAP
in adults in SSA. Our study focused on routine viral testing accompanied by testing for other pathogens as ordered by the treating physicians. With this combination
of testing, a least one potential pathogen was identified
in 57% of the study population including viruses in 48%,
pyogenic bacteria in 9%, PCP in 5% and TB in 3%. The
percentages add up to more than 57% because of the patients with coinfections. Influenza A was the most common pathogen identified in this study, found in 18
patients (24% of total); in 10 as the only pathogen identified and eight in combination with bacteria or other viruses. The original aim of the study was to recruit
patients for a full year to allow a more accurate
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assessment of seasonality; however, when the first
COVID-19 case was identified in Kenya in mid-March,
recruitment was halted at 10 months, limiting our conclusions about seasonality. However, cases occurred
throughout the 10 months of observation with no clear
seasonal trend and this finding compares with CDC Surveillance data from Kenya between 2007 to 2013 [31].
Other studies have reported variable trends including
May–July peaks in South Africa [12] and January–February peaks in Kenya [9]. The predominance of H1N1
(72%) in our study contrasts with the predominance of
H3N2 in the northern hemisphere (Radin et al., 2012),
but is consistent with data from east Africa demonstrating seasonal and year to year variability in the prevalence
of H1N1 [32, 33].
Previous retrospective and prospective studies on
pneumonia in SSA have focused predominantly on bacterial pathogens. A study from Kenya in 2000 reported
S. pneumoniae as the most common pathogen, accounting for nearly 50% of cases [34]. In the aforementioned
study, antibody testing was used for viral pathogens
allowing the identification of influenza as the etiologic
agent in 5% of patients. Their study was performed in
public hospital with a high percentage of HIV-infected
patients reported as 52% of 281 participants and half of
the S. pneumoniae cases were in HIV-infected patients.
We note that in the current series, three of the 10 HIVinfected patients had PCP as causes for their CAP, while
one had pneumococcal bacteremia and none had TB.
Other recent studies have demonstrated a wide range of
pathogens. A study in Malawi with an HIV positive adult
cohort of 94% (48/51) found that 29% bacterial infection,
27% PCP, 22% pulmonary TB and only 6% had viral infections [35]. Another study from Cameroon comparing
only clinical parameters among HIV-negative and positive adults with pneumonia reported a rate of HIV infection of 59% (62/106) (Yone et al. 2012). Several other
studies among patients with pneumonia have alluded to
the high prevalence of HIV and very little has been mentioned about NCDs [34–38].
As in many studies throughout the world, males were
more common than females [37], Underlying conditions
known to confer increased risk for CAP were identified
in 83% of patients of which the most common were cardiovascular disease, diabetes and chronic pulmonary disease. A study done in Nigeria [39], revealed 38.8% of
patients with CAP had at least one NCD. Studies from
high and middle income countries have also shown that
NCDs are common in patients presenting with pneumonia [30, 40, 41] and are linked to increased morbidity
and mortality [42–45]. The high percentage of patients
with NCDs in this study reflect the risk factors of a
growing middle class in Nairobi and may be an indication of trends relevant to SSA [5–7]. It is likely then, that
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in the setting of a low HIV prevalence, NCDs will become the major risk factors for CAP. It is therefore useful to compare results from both high HIV prevalence
settings with those from the current study from a private
hospital that has a lower percentage of HIV patients but
a higher percentage of patients with diabetes and other
chronic noncommunicable diseases.
Rhinovirus was found as frequently as influenza,
though primarily as a co-pathogen. However, there were
four cases in which it was the only agent identified. We
therefore included it in our analysis even as we recognized the controversy around its role as a lower respiratory pathogen [46–48]. Numerous other respiratory
viruses were also found, either individually or in combination with other viruses or bacteria. It is notable that
there were no cases of Mycoplasma identified, indicating
that it is not a common cause of hospitalization from
CAP.
A meta-analysis by of 31 studies from throughout the
world among adults with CAP reported that viral respiratory pathogens were identified in a pooled proportion of 24.5% (range 8–56%) [49]. Among the viruses,
influenza was the most frequently reported cause of viral
pneumonia folowed by rhinovirus, RSV and human coronaviruses. Similar findings were reported in a systematic review of 27 studies that used PCR for diagnosis of
CAP among adults in Europe where they found an average rate of 22% with a range of 6–45% [50]. Again, influenza was the most commonly identified virus, followed
by rhinovirus and human coronaviruses. Both reviews
reported a high proportion of viral pneumonia with a
dual bacterial-viral infection rate of 10% and higher
mortality rate among patients with dual infection. The
finding of viral isolates in 48% of patients in the current
study was toward the upper range of the reported
studies.
The low CURB65 and PSI scores in the current study
contrast with the high prevalence of complications on
admission including AKI, respiratory failure or sepsis
(total of 43.6% with at least one of these complications)
and requirement for critical care in 31% of patients. Notably, the two mortalities had low CURB65 and PSI
scores (PSI of 2 and 3 with CURB65 of 0 and 1). These
observations are consistent with other studies that have
shown poor ability of these scores to predict prognosis
in viral pneumonia patients [51].
This study has a few limitations. First, we recognize
that bacterial pathogens in this study were underrecognized, since bacteriologic workup was not part of
the study protocol and many patients either had no sputum submitted or had received antibiotics before the
sputum was collected. It is also possible that viral etiologies are over-stated, since viral shedding may occur in
the absence of symptoms with respiratory viruses [47,
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52–54]. However, it is noted that patients with viruses
actually had more severe disease as indicated by the
need for critical care treatment and the fact that both
mortalities were in patients with viruses. Finally, as a single center study with a 10 month duration, we were unable to address seasonality or the presence of rare
pathogens.

Conclusions
In conclusion, this study demonstrated that viral respiratory pathogens play a major role in the etiology and severity of community acquired pneumonia. It is possible
that the growth in NCDs such as diabetes and cardiovascular disease in SSA will be accompanied by an increase
in community acquired pneumonias with viral pneumonias constituting an important component, especially in
non-HIV-infected patients.
Supplementary Information
The online version contains supplementary material available at https://doi.
org/10.1186/s12879-021-06388-x.
Additional file 1.
Acknowledgments
We appreciate the contributions of the technologists in the microbiology
and molecular sections for providing high quality laboratory data. The
personnel of medical records facilitated these efforts by making the written
records readily available. We greatly appreciate the many physicians who
contributed to patient enrollment, making this study possible.
Authors’ contributions
JN – Coordinated patient recruitment, contributed to protocol design and
manuscript writing. MA – Coordinated laboratory PCR testing and analysis of
lab results, contributed to protocol design and manuscript writing. FM –
Coordinated data collection, contributed to writing. JB – Contributed to
protocol development and writing. FR – Contributed to protocol
development and writing. SG – Contributed interpretation of imaging. HP –
Contributed interpretation of imaging. RA – Guided protocol development,
data analysis and writing. The authors read and approved the final
manuscript.
Funding
No external funding was obtained for the study.
Availability of data and materials
All data generated or analyzed during this study are included in this
published article [and its supplementary information files].

Declarations
Ethics approval and consent to participate
This study was conducted following the “Guidelines and Rules Regulating
Research Involving Human Subjects” endorsed by the National Council of
Science and Technology of Kenya and approved by the Research Ethics
Committee (REC) of The Aga Khan University Nairobi, Kenya under number
2018/REC-101. Written informed consent was obtained from each of the
participants.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.

Page 8 of 9

Author details
Department of Medicine, Aga Khan University, Third Parklands Rd, Nairobi,
Kenya. 2Department of Pathology, Aga Khan University, Third Parklands Rd,
Nairobi, Kenya. 3Department of Radiology, Aga Khan University, Nairobi,
Kenya.
1

Received: 11 May 2021 Accepted: 2 July 2021

References
1. Troeger C, Forouzanfar M, Rao PC, Khalil I, Brown A, Swartz S, et al.
Estimates of the global, regional, and national morbidity, mortality, and
aetiologies of lower respiratory tract infections in 195 countries: a
systematic analysis for the global burden of disease study 2015. Lancet
Infect Dis. 2017;17(11):1133–61. https://doi.org/10.1016/S1473-3099(17)303
96-1.
2. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global,
regional, and national life expectancy, all-cause mortality, and cause-specific
mortality for 249 causes of death, 1980–2015: a systematic analysis for the
global burden of disease study 2015. Lancet. 2016;388(10053):1459–544.
https://doi.org/10.1016/S0140-6736(16)31012-1.
3. Ho A. Viral pneumonia in adults and older children in sub-Saharan Africa —
epidemiology, aetiology, diagnosis and management. Pneumonia. 2014;5(1):
18–29. https://doi.org/10.15172/pneu.2014.5/446.
4. Dwyer-Lindgren L, Cork MA, Sligar A, Steuben KM, Wilson KF, Provost NR,
et al. Mapping HIV prevalence in sub-Saharan Africa between 2000 and
2017. Nature. 2019;570(7760):189–93. https://doi.org/10.1038/s41586-019-12
00-9.
5. Martins M, Boavida JM, Raposo JF, Froes F, Nunes B, Ribeiro RT, et al.
Diabetes hinders community-acquired pneumonia outcomes in hospitalized
patients. BMJ Open Diabet Res. 2016;4(1):e000181. https://doi.org/10.1136/
bmjdrc-2015-000181.
6. Fisher-Hoch SP, Mathews CE, McCormick JB. Obesity, diabetes and
pneumonia: the menacing interface of non-communicable and infectious
diseases. Tropical Med Int Health. 2013;18(12):1510–9. https://doi.org/1
0.1111/tmi.12206.
7. Li G, Deng Q, Feng J, Li F, Xiong N, He Q. Clinical characteristics of diabetic
patients with COVID-19. J Diabet Res. 2020;2020:1–5.
8. Boyles TH, Brink A, Calligaro GL, Cohen C, Dheda K, Maartens G, et al. South
African guideline for the management of community-acquired pneumonia
in adults. J Thorac Dis. 2017;9(6):1469–502. https://doi.org/10.21037/jtd.2017.
05.31.
9. Feikin DR, Njenga MK, Bigogo G, Aura B, Aol G, Audi A, et al. Etiology and
incidence of viral and bacterial acute respiratory illness among older
children and adults in rural Western Kenya, 2007–2010. PLoS One. 2012;7(8):
e43656. https://doi.org/10.1371/journal.pone.0043656.
10. Diop D. Influenza-associated morbidity and mortality in sub-Saharan Africa.
Int J Vaccines Vaccination. 2016;2(4):2–7.
11. Widen R, Drews J. Practical Guidance for Clinical Microbiology Laboratories
2019;32(1):1–49.
12. Radin JM, Katz MA, Tempia S, Talla Nzussouo N, Davis R, Duque J, et al.
Influenza surveillance in 15 countries in Africa, 2006-2010. J Infect Dis. 2012;
206(SUPPL.1):2006–10.
13. Rose EB, Wheatley A, Langley G, Gerber S, Haynes A. Respiratory syncytial
virus seasonality - United States, 2014-2017. MMWR Morb Mortal Wkly Rep.
2018;67(2):71–6. https://doi.org/10.15585/mmwr.mm6702a4.
14. Lai AL, Millet JK, Daniel S, Freed JH, Whittaker GR. Respiratory Syncytial virus
and other Noninfluenza respiratory viruses in older adults; 2020. p. 19–20.
15. Lon S, Schneider MD, et al. Respiratory syncytial virus infection in elderly
and high-risk adults. N Engl J Med. 2015:687–96.
16. Duncan Coley B, Walsh Edward E, Peterson Derick R, Lee FEH, Falsey AR.
Risk factors for respiratory failure associated with respiratory syncytial virus
infection in adults. J Infect Dis. 2009;200(8):1242–6. https://doi.org/10.1086/
605948.
17. Panda S, Kumar N, Pena L, Kumar S. Human metapneumovirus : review of
an important respiratory pathogen. Int J Infect Dis. 2014;25:45–52. https://
doi.org/10.1016/j.ijid.2014.03.1394.
18. Branche AR, Falsey AR. Parainfluenza Virus Infection. Semin Respir Crit Care
Med. 2016;37(4):538–54. https://doi.org/10.1055/s-0036-1584798.
19. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet.
2011;377(9773):1264–75. https://doi.org/10.1016/S0140-6736(10)61459-6.

Nambafu et al. BMC Infectious Diseases

(2021) 21:703

20. To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, et al. Additional
molecular testing of saliva specimens improves the detection of respiratory
viruses. Emerg Microbes Infect. 2017;6(6):1–7.
21. Abed Y, Boivin G. Treatment of respiratory virus infections. Antivir Res. 2006;
70(2):1–16. https://doi.org/10.1016/j.antiviral.2006.01.006.
22. Kibet E, Moloo Z, Ojwang PJ, Sayed S, Mbuthia A, Adam RD. Measurement
of improvement achieved by participation in international laboratory
accreditation in sub-Saharan Africa: the Aga Khan University hospital Nairobi
experience. Am J Clin Pathol. 2014;141(2):188–95. https://doi.org/10.1309/A
JCPV8A9MRWHGXEF.
23. Anon. Section 2: AKI definition. Kidney Int Suppl. 2012;2(1):19–36.
24. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer
M, et al. The third international consensus definitions for Sepsis and septic
shock (Sepsis-3). JAMA. 2016;315(8):801–10. https://doi.org/10.1001/jama.201
6.0287.
25. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
prediction rule to identify low-risk patients with community-acquired
pneumonia. N Engl J Med. 1997;336(4):243–50. https://doi.org/10.1056/
NEJM199701233360402.
26. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI,
et al. Defining community acquired pneumonia severity on presentation to
hospital: an international derivation and validation study. Thorax. 2003;58(5):
377–82. https://doi.org/10.1136/thorax.58.5.377.
27. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al.
Prospective comparison of three validated prediction rules for prognosis in
community-acquired pneumonia. Am J Med. 2005;118(4):384–92. https://doi.
org/10.1016/j.amjmed.2005.01.006.
28. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD, Grayson
ML. Comparing the pneumonia severity index with CURB-65 in patients
admitted with community acquired pneumonia. Scand J Infect Dis. 2008;
40(4):293–300. https://doi.org/10.1080/00365540701663381.
29. Hirve S, Chadha M, Lele P, Lafond KE, Deoshatwar A, Sambhudas S, et al.
Performance of case definitions used for influenza surveillance among
hospitalized patients in a rural area of India. Bull World Health Organ. 2012;
90(11):804–12. https://doi.org/10.2471/BLT.12.108837.
30. Mocelin CA, dos Santos RP. Community-acquired pneumonia at the
Hospital de Clínicas de Porto Alegre: evaluation of a care protocol. Braz J
Infect Dis. 2013;17(5):511–5. https://doi.org/10.1016/j.bjid.2012.11.013.
31. Katz MA, Muthoka P, Emukule GO, Kalani R, Njuguna H, Waiboci LW, et al.
Results from the first six years of National Sentinel Surveillance for influenza
in Kenya, July 2007–June 2013. PLoS One. 2014;9(6):e98615. https://doi.org/1
0.1371/journal.pone.0098615.
32. Yang W, Cummings MJ, Bakamutumaho B, Kayiwa J, Owor N, Namagambo
B, et al. Dynamics of influenza in tropical Africa: temperature, humidity, and
co-circulating (sub)types. Influenza Other Respir Viruses. 2018;12(4):446–56.
https://doi.org/10.1111/irv.12556.
33. Umuhoza T, Bulimo WD, Oyugi J, Schnabel D, Mancuso JD. Prevalence and
factors influencing the distribution of influenza viruses in Kenya: seven-year
hospital-based surveillance of influenza-like illness (2007–2013). PLoS One.
2020;15(8):e0237857. https://doi.org/10.1371/journal.pone.0237857.
34. Scott JAG, Hall AJ, Muyodi C, Lowe B, Ross M, Chohan B, et al. Aetiology,
outcome, and risk factors for mortality among adults with acute pneumonia
in Kenya. Lancet. 2000;355(9211):1225–30. https://doi.org/10.1016/S0140-673
6(00)02089-4.
35. Hartung TK, Chimbayo D, van Oosterhout JJG, Chikaonda T, van Doornum
GJJ, Claas ECJ, et al. Etiology of suspected pneumonia in adults admitted to
a high-dependency unit in Blantyre, Malawi. Am J Trop Med Hygiene. 2011;
85(1):105–12. https://doi.org/10.4269/ajtmh.2011.10-0640.
36. Aston SJ, Rylance J. Community-acquired pneumonia in sub-Saharan Africa.
Semin Respir Crit Care Med. 2016;37(06):855–67.
37. Aston SJ, Ho A, Jary H, Huwa J, Mitchell T, Ibitoye S, et al. Etiology and risk
factors for mortality in an adult community-acquired pneumonia cohort in
Malawi. Am J Respir Crit Care Med. 2019;200(3):359–69. https://doi.org/10.11
64/rccm.201807-1333OC.
38. Yone EWP, Balkissou AD, Kengne AP, Kuaban C. Influence of HIV infection
on the clinical presentation and outcome of adults with acute communityacquired pneumonia in Yaounde, Cameroon: a retrospective hospital-based
study. BMC Pulmonary Med. 2012;12(1):46. https://doi.org/10.1186/1471-24
66-12-46.
39. Onyedum CC, Chukwuka J. Admission profile and management of
community acquired pneumonia in Nigeria-5 year experience in a tertiary

Page 9 of 9

40.

41.

42.

43.

44.

45.

46.

47.

48.

49.

50.

51.
52.

53.

54.

hospital. Respir Med. 2011;105(2):298–302. https://doi.org/10.1016/j.rmed.201
0.11.003.
Rosón B, Carratalà J, Dorca J, Casanova A, Manresa F, Gudiol F. Etiology,
reasons for hospitalization, risk classes, and outcomes of communityacquired pneumonia in patients hospitalized on the basis of conventional
admission criteria. Clin Infect Dis. 2001;33(2):158–65. https://doi.org/10.1
086/321808.
Feagan BG, Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK.
Treatment and outcomes of community-acquired pneumonia at Canadian
hospitals. Can Med Assoc J. 2000;162(10):1415–20.
Feldman C, Viljoen E, Morar R, Richards G, Sawyer L, Mahomed AG.
Prognostic factors in severe community-acquired pneumonia in patients
without co-morbid illness. Respirology. 2001;6(4):323–30. https://doi.org/10.1
046/j.1440-1843.2001.00352.x.
Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk
factors for Rehospitalization of patients hospitalized with communityacquired pneumonia. Clin Infect Dis. 2008;46(4):550–6. https://doi.org/10.1
086/526526.
Capelastegui A, Espana Yandiola PP, Quintana JM, Bilbao A, Diez R, Pascual
S, et al. Predictors of short-term rehospitalization following discharge of
patients hospitalized with community-acquired pneumonia. Chest. 2009;
136(4):1079–85. https://doi.org/10.1378/chest.08-2950.
Waterer GW, Kessler LA, Wunderink RG. Medium-term survival after
hospitalization with community-acquired pneumonia. Am J Respir Crit Care
Med. 2004;169(8):910–4. https://doi.org/10.1164/rccm.200310-1448OC.
Aston SJ. Pneumonia in the developing world: characteristic features and
approach to management. Respirology. 2017;22(7):1276–87. https://doi.
org/10.1111/resp.13112.
van Elden LJR, van Kraaij MGJ, Nijhuis M, Hendriksen KAW, Dekker AW,
Rozenberg-Arska M, et al. Polymerase chain reaction is more sensitive than
viral culture and antigen testing for the detection of respiratory viruses in
adults with hematological cancer and pneumonia. Clin Infect Dis. 2002;34:
177–83.
Fica A, Dabanch J, Andrade W, Bustos P, Carvajal I, Ceroni C, et al. Clinical
relevance of rhinovirus infections among adult hospitalized patients. Braz J
Infect Dis. 2015;19(2):118–24. https://doi.org/10.1016/j.bjid.2014.10.003.
Burk M, El-Kersh K, Saad M, Wiemken T, Ramirez J, Cavallazzi R. Viral
infection in community-acquired pneumonia: a systematic review and
meta-analysis. Eur Respir Rev. 2016;25(140):178–88. https://doi.org/10.1183/1
6000617.0076-2015.
Alimi Y, Lim WS, Lansbury L, Leonardi-Bee J, Nguyen-Van-Tam JS. Systematic
review of respiratory viral pathogens identified in adults with communityacquired pneumonia in Europe. J Clin Virol. 2017;95:26–35. https://doi.org/1
0.1016/j.jcv.2017.07.019.
Estella A. Usefulness of CURB-65 and pneumonia severity index for influenza
A H1N1v pneumonia. Monaldi Arch Chest Dis. 2012;77(3–4):118.
Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid
influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156(7):500–
11. https://doi.org/10.7326/0003-4819-156-7-201204030-00403.
Merckx J, Wali R, Schiller I, Caya C, Gore GC, Chartrand C, et al. Diagnostic
accuracy of novel and traditional rapid tests for influenza infection
compared with reverse transcriptase polymerase chain reaction: a
systematic review and meta-analysis. Ann Intern Med. 2017;167(6):394–409.
https://doi.org/10.7326/M17-0848.
Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older
adults. Clin Infect Dis. 2010;50(5):747–51. https://doi.org/10.1086/650486.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.

